Sushan Luo Selected Research

Sushan Luo Research Topics

Disease

13	Myasthenia Gravis 01/2022 - 01/2019
6	Muscular Diseases (Myopathy) 05/2019 - 05/2014
2	Experimental Autoimmune Myasthenia Gravis (Autoimmune Experimental Myasthenia Gravis) 01/2022 - 01/2022
2	Autoimmune Diseases (Autoimmune Disease) 01/2022 - 01/2021
2	Myotonia 05/2020 - 01/2018
2	Hypokalemic Periodic Paralysis (Periodic Paralysis, Hypokalemic) 05/2020 - 01/2018
2	Channelopathies 05/2020 - 01/2018
2	Muscular Dystrophies (Muscular Dystrophy) 05/2019 - 11/2014
2	Paralysis (Palsy) 05/2019 - 01/2018
2	Leukoencephalopathies 05/2019 - 04/2019
2	Limb-Girdle Muscular Dystrophies (Limb-Girdle Muscular Dystrophy) 01/2019 - 11/2014
2	Distal Myopathies (Distal Muscular Dystrophy) 01/2019 - 01/2019
1	Rhabdomyosarcoma 01/2022
1	Systemic Inflammatory Response Syndrome (Sepsis Syndrome) 01/2022
1	Pneumonia (Pneumonitis) 01/2022
1	Neoplasms (Cancer) 01/2022
1	Dysferlinopathy 12/2021
1	Virus Diseases (Viral Diseases) 05/2021
1	Oculopharyngodistal Myopathy 01/2021
1	Disease Progression 01/2021
1	Congenital Myasthenic Syndromes (Myasthenia Gravis, Congenital) 06/2020
1	Quadriplegia (Spastic Quadriplegia) 05/2019
1	Cognitive Dysfunction 05/2019
1	Microcephaly 04/2019
1	Charcot-Marie-Tooth Disease (Peroneal Muscular Atrophy) 04/2019
1	Vision Disorders (Hemeralopia) 04/2019
1	Nonsyndromic Deafness 04/2019
1	Thymoma (Thymic Carcinoma) 01/2019
1	Septic Shock (Toxic Shock Syndrome) 01/2019
1	Heart Arrest (Cardiac Arrest) 01/2019
1	Hyperkalemic Periodic Paralysis 01/2018
1	Hereditary Myopathy with Early Respiratory Failure 02/2015
1	Miyoshi myopathy 11/2014
1	Multiple Acyl Coenzyme A Dehydrogenase Deficiency 05/2014

Drug/Important Bio-Agent (IBA)

4	Rituximab (Mabthera)FDA Link 01/2022 - 01/2019
3	muskIBA 01/2022 - 06/2020
3	AutoantibodiesIBA 01/2022 - 01/2021
3	AntibodiesIBA 01/2022 - 12/2020
2	Serum AlbuminIBA 01/2022 - 01/2019
2	glucose-mannose-glucoseIBA 01/2021 - 01/2020
2	Cholinergic ReceptorsIBA 12/2020 - 11/2020
2	DysferlinIBA 01/2019 - 11/2014
1	Immunoglobulin G (IgG)IBA 01/2022
1	Interleukin-2 (IL2)IBA 01/2022
1	Chimeric Antigen ReceptorsIBA 01/2022
1	Interleukin-5 (Interleukin 5)IBA 01/2022
1	Interleukin-4 (Interleukin 4)IBA 01/2022
1	Complement Inactivating AgentsIBA 01/2022
1	BerberineIBA 01/2022
1	Complement System Proteins (Complement)IBA 01/2022
1	Hemoglobins (Hemoglobin)IBA 01/2022
1	Interferon Type IIBA 05/2021
1	CytokinesIBA 05/2021
1	ChemokinesIBA 05/2021
1	Toll-Like Receptors (Toll-Like Receptor)IBA 05/2021
1	Biomarkers (Surrogate Marker)IBA 01/2021
1	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 01/2021
1	5' Untranslated Regions (5' UTR)IBA 01/2021
1	MicroRNAs (MicroRNA)IBA 11/2020
1	ChloridesIBA 05/2020
1	SodiumIBA 05/2020
1	Ion Channels (Ion Channel)IBA 05/2019
1	PotassiumIBA 05/2019
1	Proteins (Proteins, Gene)FDA Link 05/2019
1	Lysine-tRNA LigaseIBA 04/2019
1	Uridine Diphosphate (UDP)IBA 01/2019
1	N-acylmannosamine kinaseIBA 01/2019
1	AcetylglucosamineIBA 01/2019
1	N-Acetylneuraminic Acid (Sialic Acid)IBA 01/2019
1	Racemases and Epimerases (Epimerases and Racemases)IBA 01/2019
1	EnzymesIBA 01/2019
1	Voltage-Gated Sodium ChannelsIBA 01/2018
1	GlycogenIBA 10/2015
1	polyglucosanIBA 10/2015
1	glycogeninIBA 10/2015
1	Adenosine Triphosphatases (ATPase)IBA 10/2015
1	ConnectinIBA 02/2015
1	N- (7- dimethylamino- 4- methylcoumarinyl)maleimide (DACM)IBA 11/2014
1	LipidsIBA 05/2014

Therapy/Procedure

2	Therapeutics 01/2022 - 12/2021
1	Aftercare (After-Treatment) 01/2021
1	Activities of Daily Living (ADL) 01/2021
1	Immunotherapy 01/2021